In fact, successful targeted therapy for HER2-amplified gastric cancer patients strongly suggests the existence of therapeutically meaningful gastric cancer subgroups,25 even if the molecular classification of that malignancy is still in its infancy. This evidence concerns the gene ERBB2 and gastric cancer.